← BioTransfer GEO Dataset Finder
GEO series

Effect of MIEN1-Based Peptide LA3IK on Gene Expression in EGF-Induced PC3 Prostate Cancer Cells at 0h, 30 Minutes, 1h, and 6h Time Points

GSE279005 Homo sapiens (human) RNA-seq (gene expression) 25 samples Submitted 2026/04/22 Platform GPL21697
At a glance

RNA-seq (gene expression) · human · 25 samples

What it is
RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism
Homo sapiens (human)
Topic
Prostate cancerThis series is part of our curated briefing on it.
Samples
25 samples: 8 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
Data you can get
A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper
An MIEN1-based hexamer peptide (LA3IK) inhibits EGF-driven oncogenic signaling in prostate cancer by disrupting EGFR-ERBB2 heterodimerizationScientific reports · 2026
Summary (written by the submitters)
This RNA-seq dataset investigates the effect of the MIEN1-based peptide LA3IK on the gene expression patterns of EGF-induced PC3 prostate cancer cells at four distinct time points: 0h (untreated), 30 minutes, 1 hour, and 6 hours. EGF stimulation was used to activate key signaling pathways involved in cell proliferation and survival, mimicking conditions associated with cancer progression.
Read the full summary ↓
The LA3IK peptide, designed to target MIEN1, was introduced to evaluate its modulatory effects on the transcriptomic response to EGF over time. By capturing the gene expression changes at these intervals, this study seeks to identify the specific molecular pathways and gene networks influenced by LA3IK, providing insights into its potential therapeutic role in modulating EGF-driven oncogenic processes in prostate cancer. The data will contribute to a better understanding of how LA3IK might disrupt tumor-promoting signals and its possible application in cancer therapy.
Published in
An MIEN1-based hexamer peptide (LA3IK) inhibits EGF-driven oncogenic signaling in prostate cancer by disrupting EGFR-ERBB2 heterodimerization
Tripathi AK, Ahamad N, Tyagi A et al. · Scientific reports 2026 · PMID 41786898 · doi:10.1038/s41598-026-41933-1
This dataset
Open GSE279005 in finder → Find more human RNA-seq datasets → Prostate cancer landscape →
Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓
2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE279005_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓
3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1169901 and SRA study SRP537310. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 41786898) ↗
Study design
8 conditions, mostly in triplicate
EGF (10ng/mL) treated PC3 cells 0h ×3 EGF (10ng/mL)+ LA3IK (80 µM) treated PC3 cell… ×3 EGF (10ng/mL) treated PC3 cells 30 minutes ×3 EGF (10ng/mL)+ LA3IK (80 µM) treated PC3 cell… ×3 EGF (10ng/mL) treated PC3 cells 1h ×3 EGF (10ng/mL)+ LA3IK (80 µM) treated PC3 cell… ×3 EGF (10ng/mL) treated PC3 cells 6h ×3 EGF (10ng/mL)+ LA3IK (80 µM) treated PC3 cell… ×3 +1 more

Supports a between-group comparison across 24 samples.

How we read this: 8 replicated groups read from 25 sample titles; they account for 24 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study
More Prostate cancer datasets

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.